Health care policies on California’s marketplace have already grown more costly. Federal subsidies, soon to go away, will push rates up more than 10%.

Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.